Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Atypical antipsychotics in older adults.

Y C Chan1, S F Pariser, G Neufeld

  • 1Department of Psychiatry, Ohio State University, Columbus 43210-1250, USA.

Pharmacotherapy
|July 23, 1999
PubMed
Summary

Atypical antipsychotics are effective for older adults with psychotic symptoms, but more research is needed due to age-related factors and limited elderly-specific studies. Careful consideration of comorbidities and side effects is crucial for safe and effective treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Meta-analysis of the effects of bovine in vitro embryo production on gene expression.

Animal : an international journal of animal bioscience·2025
Same author

Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.

Oncogene·2025
Same author

Correction: Modeling invasive breast cancer: growth factors propel progression of HER2-positive premalignant lesions.

Oncogene·2024
Same author

Successful endovascular treatment in a COVID-19 patient with mycotic aortoiliac aneurysm due to <i>Salmonella typhi</i>: a case report.

Hong Kong medical journal = Xianggang yi xue za zhi·2024
Same author

Custom-made double inner-branched aortic arch endograft for the treatment of mycotic aortic arch aneurysm: a case report.

Hong Kong medical journal = Xianggang yi xue za zhi·2021
Same author

Observation of void formation patterns in SnAg films undergoing electromigration and simulation using random walk methods.

Scientific reports·2021

Area of Science:

  • Geriatric Psychiatry
  • Clinical Pharmacology
  • Psychopharmacology

Background:

  • Psychotic symptoms are prevalent in older adults, often linked to diverse psychiatric and medical conditions.
  • Treatment with antipsychotic drugs is complicated in the elderly by comorbidities, side effect risks, and age-related physiological changes.
  • Current knowledge on antipsychotic use in older adults relies heavily on studies of younger populations or small-sample elderly studies.

Purpose of the Study:

  • To review psychiatric and medical conditions associated with psychotic symptoms in older adults.
  • To discuss the benefits of antipsychotic treatment in this demographic.
  • To highlight the need for more robust research on antipsychotic safety and efficacy in the elderly.

Main Methods:

Related Experiment Videos

  • Review of existing literature on psychotic symptoms in older adults.
  • Analysis of the role of antipsychotic medications, particularly atypical antipsychotics.
  • Examination of challenges and considerations in treating elderly patients with psychotic disorders.

    • Main Results:

    • Atypical antipsychotics demonstrate superior safety and efficacy, establishing them as first-line agents for schizophrenia and other psychotic disorders in older adults.
    • Established uses include schizophrenia, schizoaffective disorders, delusional disorder, and mood disorders with psychotic features.
    • Significant gaps exist in well-designed, placebo-controlled studies specifically in the elderly population.

    Conclusions:

    • Atypical antipsychotics offer significant benefits for older adults experiencing psychotic symptoms.
    • Further well-designed studies are essential to optimize the safety, efficacy, and dosing of these agents in geriatric populations.
    • Comprehensive management requires careful consideration of comorbid medical conditions and age-specific pharmacokinetic and pharmacodynamic changes.